Peptides for Fat Loss & Body Recomposition

How peptide Targets Peptides for Fat Loss

Pharmacologic fat loss with peptides works through three mechanisms: appetite suppression via central GLP-1 receptors (semaglutide, tirzepatide, liraglutide), visceral adipose mobilization via GHRH-driven GH elevation (tesamorelin, CJC-1295), and lipolytic or mitochondrial biasing via niche agents (AOD-9604, MOTS-c, 5-amino-1MQ).

The clinically dominant path is GLP-1/GIP agonism — semaglutide and tirzepatide have 15–22% mean weight reduction in controlled trials and are FDA-approved for this indication. Everything else operates at substantially lower magnitudes and with thinner evidence.

For visceral-fat-specific reduction, tesamorelin has the strongest data: the 26-week phase-3 program showed ~15% VAT reduction in HIV lipodystrophy and subsequent research extends this to non-HIV metabolic populations. The GHS approach is slower and more targeted to visceral depots than GLP-1s.

Research peptides like AOD-9604 (a fragment of GH 176-191 proposed to mimic GH's lipolytic activity) and 5-amino-1MQ (a non-peptide NNMT inhibitor often grouped with peptides) have interesting preclinical data but sparse human evidence.